Swiss biopharma company Relief Therapeutics has launched its next-generation medical food product PKU GOLIKE in the US for the dietary management of phenylketonuria (PKU).
PKU is a rare hereditary condition that causes an accumulation of phenylalanine when ingesting protein- or aspartame-containing meals.
PKU GOLIKE is said to be a phenylalanine-free food developed for special medical purposes (FSMP). It comprises a blend of amino acids in the form of granules.
Designed with Relief Therapeutics’ patented Physiomimic Technology platform, the product will be available in medical food bars and convenient packets.
According to the Swiss biopharma company, PKU GOLIKE is the first prolonged-release amino acid supplement, distinguished by a coating that guarantees physiological amino acid absorption, similar to that of natural proteins.
The coating is said to cover up the amino acids’ unpleasant aftertaste, odour, and taste, said Relief Therapeutics.
Relief Therapeutics board of directors chairman Raghuram Selvaraju said: “As the first controlled-release, taste- and odor-masked food for special medical purposes, PKU GOLIKE offers the potential for better metabolic management and improved compliance for patients who must contend with lifelong dietary restrictions associated with PKU.
“With our team of seasoned commercial leaders with significant rare disease launch experience in place, combined with our recently executed agreement with a leading medical nutrition provider for patient access and support services, we are well positioned to launch PKU GOLIKE into the U.S. market and to continue our mission of commercializing best-in-class, patented products in the ultra-rare disease space.”
The US rollout of PKU GOLIKE marks the completion of a milestone that was agreed contractually between the Swiss biopharma company and the former shareholders of APR Applied Pharma Research.
Relief Therapeutics said that the first sale of PKU GOLIKE in the US is intended through its exclusive national distributor.
